Financial Data and Key Metrics Changes - Revenue in Q1 fiscal 2026 increased more than four times to $21.4 million compared to $4.6 million in Q1 fiscal 2025 [16] - Gross margin increased significantly to 78.6% in Q1 fiscal 2026 from 24.5% in Q1 fiscal 2025, primarily driven by staking revenue from the Solana treasury strategy [16] - Net loss for Q1 fiscal 2026 was approximately $585.6 million, compared to a net loss of $0.7 million in Q1 fiscal 2025, largely due to a decline in the fair value of SOL holdings [18] Business Line Data and Key Metrics Changes - Forward held approximately 6,962,501 Solana as of December 31, 2025, with over 99% staked, generating a staking yield between 6.5% and 7.2% [13] - Fully diluted SOL per share increased from 0.0604 at the end of September 2025 to 0.0624 at the end of December 2025, representing a growth of roughly 13% in the fiscal first quarter [14] Market Data and Key Metrics Changes - Solana continues to lead in key metrics such as decentralized exchange trading volumes, active users, and developer engagement, demonstrating resilience and performance [6][7] - Institutional engagement has expanded significantly, with major financial institutions and payment platforms integrating with Solana [7] Company Strategy and Development Direction - The company aims to build a permanent capital vehicle that participates directly in the growth of the Solana ecosystem, evolving beyond a treasury into an active value-generating business [5] - Forward Industries is focused on compounding SOL per share by engaging directly in economic activities on-chain rather than relying solely on passive exposure [6] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the volatility in the market but emphasizes that Solana is now being evaluated based on actual performance rather than theoretical scalability [6] - The company believes the opportunity in front of Solana is increasingly clear, with a focus on long-term growth and responsible risk management [5][6] Other Important Information - Forward became one of the first public companies to have its SEC-registered shares live on a public blockchain, enhancing its operational capabilities [8] - The company launched fwdSOL, a proprietary liquid staking token, representing approximately 25% of its SOL holdings, allowing for efficient deployment of staked SOL [9] Q&A Session Summary Question: How does the company view recent token price volatility? - Management noted that SOL is down approximately 70% from its all-time high, which is typical in the crypto market, and emphasized maintaining a clean balance sheet [19][20] Question: What is the company's approach to potential M&A? - The company is looking for accretive acquisitions and is well-positioned to capitalize on opportunities due to its lack of institutional debt [23][24] Question: How should shareholders view SOL per share as a performance metric? - SOL per share growth is considered the North Star KPI, with a target to consistently generate returns greater than the staking yield [24] Question: What is the expected trend for staking yields as Solana network usage grows? - Management clarified that increased validator participation does not impact yields for stakers, and they expect yields to increase with network activity [43][44] Question: Can you clarify the nature of related party G&A expenses? - Related party expenses are associated with the launch of the digital asset treasury strategy and are expected to decrease in the coming months [50]

Financial Data and Key Metrics Changes - Total revenue decreased by approximately $3 million or 2.7% to approximately $108.5 million for the quarter ended December 31, 2025, compared to $111.5 million in the prior year period [4] - Operating income increased by approximately $2.7 million or 352.9% to $3.5 million for the first quarter, compared to approximately $800,000 in the prior year period [9] - Adjusted EBITDA for the first quarter was approximately $7.8 million, an increase of approximately $2 million or 35.7% compared to $5.7 million in the prior year period [10] Business Line Data and Key Metrics Changes - Retail-Flooring segment revenue for the first quarter was approximately $25.3 million, down $6.4 million or 20.2% compared to $31.7 million in the prior year period, primarily due to changes in store footprint and softness in the housing market [5] - Flooring Manufacturing segment revenue for the first quarter was approximately $28.9 million, a decrease of approximately $300,000 or 1.1% compared to approximately $29.2 million in the prior year period [6] - Steel Manufacturing segment revenue for the first quarter was approximately $31.9 million, a decrease of approximately $1.4 million or 4.3% compared to approximately $33.3 million in the prior year period [7] Market Data and Key Metrics Changes - The decline in revenue was primarily attributable to a $7.1 million decline in the Retail-Flooring and Steel Manufacturing segments, partially offset by a $4.1 million increase in the Retail-Entertainment and Flooring Manufacturing segments [4] - Retail-Entertainment segment revenue for the first quarter was approximately $23.6 million, an increase of approximately $2.3 million or 11% compared to $21.3 million in the prior year period [4] Company Strategy and Development Direction - The company is rolling out a comprehensive strategy to integrate AI across business units to modernize operations and improve efficiency [11] - By applying AI alongside robotics and data analytics, the company aims to reinforce cost discipline that supports its long-term strategy [12] Management's Comments on Operating Environment and Future Outlook - Management noted that the portfolio companies continued to strengthen their operating disciplines and optimize cost structures despite sustained softness in new home construction and home refurbishment markets [3] - The company delivered a solid first quarter marked by meaningful operating improvements across the businesses, despite a challenging housing market backdrop [11] Other Important Information - Gross profit was approximately $35.4 million for the first quarter, essentially unchanged compared to the prior year period, but gross margin increased by 90 basis points to 32.6% [8] - General and administrative expense decreased approximately $2.2 million or 7.4% to approximately $27.8 million, driven by targeted cost reduction initiatives [9] Q&A Session Summary Question: Are there any questions from the participants? - There were no questions from the participants during the Q&A session [13]

Bio-Rad Laboratories (NYSE:BIO) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Company ParticipantsEdward Chung - VP of Investor RelationsJon DiVincenzo - President and COONorman Schwartz - CEORoop Lakkaraju - EVP and CFOConference Call ParticipantsDan Leonard - Managing Director and Senior Equity Research AnalystJack Meehan - Partner and Senior Equity Research AnalystTycho Peterson - Managing Director and Senior Equity Research AnalystOperatorGood day, everyone, and welcome to the Bio-Rad fourth quart ...

Atomera (NasdaqCM:ATOM) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Company ParticipantsFrank Laurencio - CFOMike Bishop - Investor RelationsScott Bibaud - CEOConference Call ParticipantsRichard Shannon - AnalystMike BishopHello everyone, and welcome to Atomera's fourth quarter and fiscal year 2025 update call. I'd like to remind everyone that this call and webinar are being recorded, and a replay will be available on Atomera's IR website for one year. I'm Mike Bishop with the company's investor rel ...

Financial Data and Key Metrics Changes - Net sales for Q4 2025 were approximately $693 million, a 3.9% increase from $668 million in Q4 2024. On a currency neutral basis, this represents a 1.7% year-over-year increase driven by the clinical diagnostics segment [11] - Full year net sales for 2025 were $2.583 billion, a 0.7% increase from $2.567 billion in 2024. On a currency neutral basis, sales were essentially flat compared to 2024 [18] - Q4 GAAP gross margin was 49.8%, down from 51.2% in Q4 2024. Non-GAAP gross margin was 52.5%, compared to 53.9% in the previous year [13][14] - Full year non-GAAP gross margin was 53.3%, down from 55% in 2024, primarily due to reduced fixed manufacturing absorption and higher material costs [20] Business Segment Data and Key Metrics Changes - Clinical diagnostics segment sales in Q4 2025 were approximately $425 million, an increase of 8.4% on a reported basis from $393 million in Q4 2024, driven by higher sales of quality control and blood typing products [13] - Life science segment sales in Q4 2025 were $268 million, a 2.6% decrease from $275 million in Q4 2024, impacted by a constrained academic research and biotech funding environment [11] - The ddPCR portfolio posted mid-single-digit year-over-year growth in Q4, driven by the success of the QX700 platform [12] Market Data and Key Metrics Changes - Currency neutral sales decreased in the Americas, partially offset by increased sales in EMEA and Asia Pacific [12] - In biopharma, funding conditions improved during the second half of 2025, with expectations for a modest recovery in 2026 [9] - Academic institutions remain cautious in spending, focusing on maintaining staffing levels rather than purchasing capital equipment [8] Company Strategy and Development Direction - The company plans to advance several product launches in 2026, including an IVD version of the QX600 and additional high-value ddPCR assays across oncology [10] - Bio-Rad remains focused on disciplined innovation as a core part of its long-term growth strategy [9] - The company is looking for additional assets to help accelerate top-line growth and margin expansion [31] Management's Comments on Operating Environment and Future Outlook - Management noted early signs of stabilization across core markets, with improvements in NIH funding and biopharma funding [29] - The company is confident that actions taken to improve operational performance and expand margins will translate into better financial results over time [10] - Management remains cautious about the potential impact of policy developments in China on reimbursement rates [6] Other Important Information - Free cash flow for the full year 2025 improved to approximately $375 million, representing a conversion ratio of 138% for free cash flow to non-GAAP net income [23] - The company retired 1.2 million shares through its buyback program at a total cost of approximately $296 million during 2025 [23] Q&A Session Summary Question: Can you elaborate on the ddPCR business growth and the contribution from Stilla? - Management indicated that the strong growth was driven by the QX700 platform and a large installed base, with ongoing reagents being a significant part of the portfolio [35][36] Question: What are the recent changes affecting Process Chromatography? - Management explained that changes in vaccine production strategies and government regulations impacted demand, leading to a conservative outlook for this segment [38] Question: What is the outlook for operating margins in 2026? - Management provided a realistic outlook, factoring in the impact of Process Chromatography and operational improvements, guiding for an operating margin between 12% and 12.5% [39][41] Question: Why is clinical diagnostics growth muted compared to pre-COVID levels? - Management attributed the muted growth to a mix of product performance and geographic factors, particularly reliance on markets like China [60] Question: What is the long-term growth outlook for Process Chromatography? - Management suggested a possibility of returning to low single-digit growth by 2027, with potential for acceleration depending on customer transitions from clinical to commercial phases [62]

Pacific Biosciences of California (NasdaqGS:PACB) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker9Good day, and welcome to PacBio's fourth quarter and full year 2025 earnings conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad, and t ...

Airbnb (NasdaqGS:ABNB) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker10Good afternoon, and thank you for joining Airbnb's earnings call, conference call for the fourth quarter of 2025. As a reminder, this conference call is being recorded and will be available for replay from the investor relations section of Airbnb's website following this call. I will now hand the call over to Andrew Slabin, Vice President of Investor Relations. Please go ahead.Speaker0Good afternoon, and welcome to Airbnb's ...

Financial Data and Key Metrics Changes - In fiscal year 2025, total revenue was $531.8 million, up 24% year-over-year [6][19] - Q4 total revenues reached $145.3 million, a 25% increase year-over-year [19] - Cloud revenue for 2025 was $243.3 million, representing 45% year-over-year growth [6][20] - Q4 cloud revenues grew to $70.2 million, up 42% year-over-year, accounting for 48% of total revenues [19][20] - Gross profit in Q4 was $121.6 million, with a gross margin of 83.7% [24] - Non-GAAP earnings per share for 2025 was $0.82, a 26% increase year-over-year [25] Business Line Data and Key Metrics Changes - Customers spending more than $100,000 annually grew to 1,168, a 15% increase year-over-year [6] - Enterprise Plus subscriptions contributed 57% of total revenues in Q4, up from 54% in the prior year [21] - Security Core products represented 16% of remaining performance obligation (RPO) as of December 31, 2025, compared to 12% in the prior year [23] Market Data and Key Metrics Changes - JFrog's customer count in fiscal year 2025 was approximately 6,600 [23] - Net Dollar Retention for the four trailing quarters was 119%, indicating strong customer adoption [23] Company Strategy and Development Direction - JFrog aims to be the system of record for managing and securing software supply chains, particularly in the context of AI [10][18] - The company is focusing on expanding its security offerings and enhancing partnerships with major cloud providers [14][18] - JFrog is committed to quality growth and responsible investments while addressing emerging needs in the software supply chain [33] Management's Comments on Operating Environment and Future Outlook - Management noted a growing threat environment in software supply chains, which is driving demand for JFrog's security solutions [12][44] - The company anticipates continued durable growth in cloud revenue, estimating a baseline growth of 30%-32% for 2026 [28] - Management expressed confidence in the strength of the pipeline and a stabilized purchasing environment as they enter 2026 [27] Other Important Information - JFrog's cash and short-term investments totaled $704 million at the end of 2025, up from $522 million at the end of 2024 [26] - The company is focused on maintaining disciplined spending while investing in innovation across its platform [29] Q&A Session Summary Question: Customer count transition and focus on larger customers - Management confirmed a strategy focused on larger enterprise customers, resulting in a decrease in lower ASP customers while increasing spending from larger clients [39][40] Question: Structural growth drivers from security incidents - Management acknowledged the increasing frequency of security incidents as a structural growth driver, emphasizing the need for robust security solutions [43][44] Question: Revenue parallels from security incidents - Management indicated that potential revenue growth should be assessed based on the number of enterprise customers yet to adopt JFrog Security, highlighting multiple avenues for growth [48] Question: Consumption trends from AI-driven deployments - Management noted a significant increase in binaries created due to AI agents, indicating a growing need for JFrog's solutions to manage this surge [52] Question: Governance and regulatory pressure with AI adoption - Management confirmed that JFrog's AppTrust is designed to address governance challenges arising from AI and generative tools [56] Question: Partnerships with AI companies and new logos - Management highlighted that partnerships with NVIDIA and Hugging Face are driving new customer acquisitions and enhancing JFrog's position in the market [72][73] Question: Risks associated with AI - Management identified the risk of becoming distracted by trends rather than focusing on delivering value to enterprise customers as a key concern [80]

Financial Data and Key Metrics Changes - As of December 31, 2025, the company had $61.8 million in cash, cash equivalents, and marketable securities, reflecting a focus on cash preservation measures to enhance operational efficiency and extend runway [9][58]. Business Line Data and Key Metrics Changes - The company completed the randomized portion of the PALISADE-3 phase 3 trial in social anxiety disorder and is now focused on the ongoing PALISADE-4 trial, implementing refinements based on insights from PALISADE-3 [4][7]. - The open-label extension of PALISADE-3 and PALISADE-4 is ongoing, aimed at evaluating the safety and tolerability of fasedienol in real-world situations [6]. Market Data and Key Metrics Changes - The company is preparing to submit a US investigational new drug application for rafisolone, a hormone-free product candidate for treating moderate to severe vasomotor symptoms due to menopause, with a planned submission in the first half of 2026 [8][9]. Company Strategy and Development Direction - The company aims to deliver transformative treatments for social anxiety disorder and women's health, focusing on data-driven approaches and regulatory strategies that leverage the totality of evidence from its clinical programs [10]. - The strategic focus includes enhancing statistical models and understanding predictors of response to improve regulatory discussions with the FDA [5][7]. Management's Comments on Operating Environment and Future Outlook - Management emphasized the significant unmet need in social anxiety disorder and the commitment to advancing clinical programs that could provide meaningful value to patients and shareholders [10]. - The company is closely monitoring the evolving regulatory landscape, particularly the integration of AI in decision-making processes at the FDA [32]. Other Important Information - The company has implemented company-wide cash preservation measures to maintain strategic flexibility across its pipeline [9]. - Insights from ongoing studies are expected to contribute to a better understanding of fasedienol's drug effect and usage patterns [7]. Q&A Session Summary Question: Insights from PALISADE-3 data - The company is still analyzing the data from PALISADE-3 and has not released individual curves publicly, but differences have been noted in individual respondents and subgroups [12][13]. Question: Modifications to the SAP plan - Any future changes to the SAP would require resubmission and alignment with the FDA before database lock [18][20]. Question: Enrollment status for PALISADE-4 - Enrollment for PALISADE-4 has continued as planned and projected, with no impact observed since the announcement on December 17 [36][37]. Question: Regulatory path forward - The regulatory outcomes depend on the totality of data and the nature of the population in need, with a focus on the weight of evidence across the program [31][32]. Question: Impact of PALISADE-3 outcome on PALISADE-4 - The company is exploring potential covariates from previous studies that may influence the separation between treatment arms, but no guarantees can be made [38][39].

Bright Horizons Family Solutions (NYSE:BFAM) Q4 2025 Earnings call February 12, 2026 05:00 PM ET Speaker6Greetings, and welcome to the Bright Horizons Family Solutions fourth quarter 2025 earnings call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Mich ...